Natural Product (NP) Details

General Information of the NP (ID: NP9303)
Name
1-deoxynojirimycin
Synonyms
1-DEOXYNOJIRIMYCIN; 19130-96-2; DUVOGLUSTAT; Moranoline; deoxynojirimycin; (2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Deoxy-1,5-imino-D-mannitol; Moranolin; 1,5-Dideoxy-1,5-imino-D-glucitol; UNII-FZ56898FLE; C6H13NO4; D-1-deoxynojirimycin; (+)-1-DEOXYNOJIRIMYCIN; S-GI; (2R,3R,4R,5S)-2-Hydroxymethyl-piperidine-3,4,5-triol; 1-deoxynojirimycin (DNJ); 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R,3R,4R,5S)-; CHEMBL307429; FZ56898FLE; DNJ; CHEBI:44369; 1-Deoxy-Nojirimycin; MFCD00063474; 5-Amino-1,5-dideoxy-D-glucopyranose; (2R,3R,4R,5S)-2-(Hydroxymethyl)-3,4,5-piperidinetriol; 1 Deoxynojirimycin; 1oim; Antibiotic S-GI; BAY-h-5595; DNM; 70956-02-4; Duvoglustat [USAN:INN]; BAY-h 5595; 1-Deoxynojirimicin; NOJ; PubChem21441; Duvoglustat (USAN/INN); EC 606-239-2; SCHEMBL2969; 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))-; BSPBio_000993; GTPL4642; BDBM18351; DTXSID70172647; 2j77; Bio1_000415; Bio1_000904; Bio1_001393; HMS1792A15; HMS1990A15; HMS3267J09; HMS3403A15; 1,5-dideoxy-1,5-imino-d-glucito; AMY37043; ZINC3794714; s3839; 1,5-didesoxy-1,5-imino-D-glucitol; 1, 5-dideoxy-1,5-imino-D-glucitol; AKOS006275143; 1-Deoxynojirimycin, analytical standard; AC-1386; CCG-266301; CS-5594; DB03206; SMP2_000333; NCGC00025085-02; NCGC00025085-03; BS-15755; HY-14860; S606; N1659; 30D962; A14383; C16843; D09605; SR-01000597392; Q-100789; SR-01000597392-1; W-201703; Q15274561; (2R,3R,4R,5S)-2-(Hydroxymethyl)piperidine-3,4,5-triol, 10
    Click to Show/Hide
Species Origin Commelina communis ...     Click to Show/Hide
Commelina communis
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Commelinales
Family: Commelinaceae
Genus: Commelina
Species: Commelina communis
Disease Inborn carbohydrate metabolism error [ICD-11: 5C51] Phase 3 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -6.1
 
MDCK Permeability
 -4.912
 
PAMPA
 +++
 
HIA
 -
 
Distribution
VDss
 -0.478
 
PPB
 20%
 
BBB
 - -
 
Metabolism
CYP1A2 inhibitor
 - - -
CYP1A2 substrate
 - - -
CYP2C19 inhibitor
 - - -
CYP2C19 substrate
 - - -
CYP2C9 inhibitor
 - - -
CYP2C9 substrate
 - -
CYP2D6 inhibitor
 - - -
CYP2D6 substrate
 - - -
CYP3A4 inhibitor
 - - -
CYP3A4 substrate
 - - -
CYP2B6 inhibitor
 - -
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 +++
HLM Stability
 - - -
 
Excretion
CLplasma
 3.535
 
T1/2
 2.055
Toxicity
DILI
 - -
 
Rat Oral Acute Toxicity
 - - -
 
FDAMDD
 - - -
 
Respiratory
 - - -
 
Human Hepatotoxicity
 -
 
Ototoxicity
 ++
 
Drug-induced Nephrotoxicity
 ++
 
Drug-induced Neurotoxicity
 - - -
 
Hematotoxicity
 -
 
Genotoxicity
 - - -
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C6H13NO4
PubChem CID
29435
Canonical SMILES
C1C(C(C(C(N1)CO)O)O)O
InChI
1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5-,6-/m1/s1
InChIKey
LXBIFEVIBLOUGU-JGWLITMVSA-N
CAS Number
CAS 19130-96-2
ChEBI ID
CHEBI:44369
Herb ID
HBIN002487
SymMap ID
SMIT15002
TTD Drug ID
D0S5LT
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Indomethacin      Rheumatoid arthritis     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Phosphorylation p105  Molecule Info 
Pathway MAP
                    In-vivo Model A GU mouse model was induced by indomethacin
                    Experimental
                    Result(s)		 DNJ showed protection for gastric functions of GU mice by reducing the levels of MOT and SP, and increasing the levels of SS and VIP.
          Ibuprofen      Pain     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Animal models of Parkinson's disease (PD) were used in this study.
                    Experimental
                    Result(s)		 MPTP induced death of dopaminergic neurons, microgliosis, increase of gliapses, motor impairment and neuroinflammation in mice, which were inhibited by combined 1-deoxynojirimycin and ibuprofen treatment.
Target and Pathway
Target(s) Intestinal maltase-glucoamylase (MGAM)  Molecule Info  [4]
Lysosomal alpha-glucosidase (GAA)  Molecule Info  [5]
KEGG Pathway Galactose metabolism Click to Show/Hide
2 Starch and sucrose metabolism
3 Metabolic pathways
4 Carbohydrate digestion and absorption
5 Lysosome
Pathwhiz Pathway Starch and Sucrose Metabolism Click to Show/Hide
2 Galactose Metabolism
Pathway Interaction Database Notch-mediated HES/HEY network Click to Show/Hide
WikiPathways Metabolism of carbohydrates Click to Show/Hide
References
Reference 1 The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum Mutat. 2009 Dec;30(12):1683-92.
Reference 2 1-Deoxynojirimycin (DNJ) Ameliorates Indomethacin-Induced Gastric Ulcer in Mice by Affecting NF-kappaB Signaling Pathway. Front Pharmacol. 2018 Apr 19;9:372.
Reference 3 Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration in MPTP-Treated Mice. J Neuroimmune Pharmacol. 2021 Jun;16(2):390-402.
Reference 4 Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
Reference 5 In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link